Mainstream

Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs

Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs

Post ContentvxrtRead More

You might also be interested in reading Kellanova raises quarterly dividend by 1.85 to $0.58/share.

May 14, 2025
In Mainstream